Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Booming Clinical Research Business Could Trigger Regulatory Overhaul In India

This article was originally published in PharmAsia News

Executive Summary

SAN FRANCISCO - Foreign companies could soon get the go-ahead to conduct Phase I studies in India, as part of a national regulatory overhaul spurred on by booming clinical research business, regional experts say

You may also be interested in...



Wyeth Defends Clinical Trial Standards After Indian Baby’s Death

NEW DELHI - Wyeth has defended its "high-quality" clinical patient trial standards after India's drug quality regulator ordered a review of trials for an advanced pneumonia vaccine by the Indian unit of the U.S. pharmaceutical giant following the death of a baby

Wyeth Defends Clinical Trial Standards After Indian Baby’s Death

NEW DELHI - Wyeth has defended its "high-quality" clinical patient trial standards after India's drug quality regulator ordered a review of trials for an advanced pneumonia vaccine by the Indian unit of the U.S. pharmaceutical giant following the death of a baby

India May Soon Allow Outside Phase I Drug Studies

Certain studies by multinational drug companies would be allowable under pending changes to India’s clinical trial regulations.

Related Content

UsernamePublicRestriction

Register

LL1134044

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel